Equities research analysts forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will post ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Intellia Therapeutics’ earnings. The lowest EPS estimate is ($0.78) and the highest is ($0.48). Intellia Therapeutics posted earnings per share of ($0.51) in the same quarter last year, which suggests a negative year over year growth rate of 15.7%. The company is expected to issue its next earnings results on Tuesday, May 7th.

According to Zacks, analysts expect that Intellia Therapeutics will report full-year earnings of ($2.59) per share for the current financial year, with EPS estimates ranging from ($3.35) to ($1.84). For the next year, analysts expect that the firm will report earnings of ($2.62) per share, with EPS estimates ranging from ($3.81) to ($1.68). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, February 27th. The company reported ($0.43) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.12. The business had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $9.92 million. Intellia Therapeutics had a negative net margin of 280.42% and a negative return on equity of 30.59%. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.61) earnings per share.

Several brokerages have weighed in on NTLA. BidaskClub cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Evercore ISI began coverage on shares of Intellia Therapeutics in a research note on Thursday, April 11th. They set an “outperform” rating on the stock. Zacks Investment Research cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Chardan Capital reaffirmed a “buy” rating and set a $57.50 price objective on shares of Intellia Therapeutics in a research note on Wednesday, February 27th. Finally, BTIG Research began coverage on shares of Intellia Therapeutics in a report on Thursday, February 7th. They issued a “buy” rating and a $20.00 price objective on the stock. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Intellia Therapeutics currently has an average rating of “Hold” and an average price target of $29.08.

Intellia Therapeutics stock traded down $0.06 during trading hours on Tuesday, hitting $16.15. 484,192 shares of the stock were exchanged, compared to its average volume of 434,313. The stock has a market capitalization of $734.49 million, a price-to-earnings ratio of -8.16 and a beta of 2.95. Intellia Therapeutics has a 12 month low of $11.03 and a 12 month high of $32.95.

In other news, EVP Andrew Schiermeier acquired 7,500 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of $15.72 per share, with a total value of $117,900.00. Following the transaction, the executive vice president now directly owns 3,250 shares in the company, valued at approximately $51,090. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of NTLA. Ontario Teachers Pension Plan Board acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $22,659,000. Rehmann Capital Advisory Group acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth about $14,409,000. Vanguard Group Inc lifted its stake in shares of Intellia Therapeutics by 12.2% during the 3rd quarter. Vanguard Group Inc now owns 2,653,165 shares of the company’s stock worth $75,934,000 after buying an additional 287,682 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Intellia Therapeutics by 12.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,653,165 shares of the company’s stock worth $75,934,000 after buying an additional 287,682 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Intellia Therapeutics by 75.5% during the 4th quarter. Deutsche Bank AG now owns 635,956 shares of the company’s stock worth $8,680,000 after buying an additional 273,501 shares during the last quarter. Institutional investors own 69.64% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Further Reading: Ex-Dividend

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.